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Introduction
Visceral fat accumulation, a key feature of the metabolic syn-
drome, is associated with the development of diabetes mellitus, a
three-fold increased risk of developing coronary heart disease [1],
a two to three times increase in cardiovascular mortality [2] and
worse clinical outcome following an acute myocardial infarction
[3–5] or a primary percutaneous coronary intervention [6].
Although formerly regarded as purely an energy storage site, the
emerging studies suggest that adipose tissue is an active
endocrine organ producing ‘adipocytokines’, hormones that influ-
ence a diverse array of processes including appetite and energy 
balance, immunity, insulin sensitivity, angiogenesis, blood pressure,
lipid metabolism and haemostasis, all factors that can impact
cardiovascular disease [7]. In this regard, the adipocytokines,
adiponectin [8], leptin [9] and apelin [10], have been linked to
cardioprotection in recent experimental studies.
The recently discovered adipocytokine, visfatin, has been
demonstrated to mimic the glucose-lowering effect of insulin and
improve insulin sensitivity [11]. Furthermore, by binding to the
insulin receptor, visfatin has been demonstrated to activate intra-
cellular kinase signalling cascades, such as the PI3K-Akt and mito-
gen-activated protein kinase (MAPK) pathways [11], through
which it may exert an antiapoptotic effect [12]. Experimental stud-
ies have indicated that the activation of pro-survival protein kinas-
es such as PI3K-Akt and MEK1/2-Erk1/2 MAPK, at the time of
myocardial reperfusion [13, 14], confers powerful cardioprotec-
tion, an effect attributable, in part, to the inhibition of the mito-
chondrial permeability transition pore (mPTP) [15]. The mPTP is
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Visfatin is an adipocytokine capable of mimicking the glucose-lowering effects of insulin and activating the pro-survival kinases phos-
phatidylinositol-3-OH kinase (PI3K)-protein kinase B (Akt) and mitogen-activated protein kinase kinase 1 and 2 (MEK1/2)-extracellular
signal-regulated kinase 1 and 2 (Erk 1/2). Experimental studies have demonstrated that the activation of these kinases confers cardiopro-
tection through the inhibition of the mitochondrial permeability transition pore (mPTP). Whether visfatin is capable of exerting direct
cardioprotective effects through these mechanisms is unknown and is the subject of the current study. Anaesthetized C57BL/6 male mice
were subjected to in situ 30 min. of regional myocardial ischaemia and 120 min. of reperfusion. The administration of an intravenous bolus
of visfatin (5  10
6 mol) at the time of myocardial reperfusion reduced the myocardial infarct size from 46.1  4.1% in control hearts
to 27.3  4.0% (n  6/group, P  0.05), an effect that was blocked by the PI3K inhibitor, wortmannin, and the MEK1/2 inhibitor, U0126
(48.8   5.5% and 45.9  8.4%, respectively, versus 27.3   4.0% with visfatin; n  6/group,  P  0.05). In murine ventricular
cardiomyocytes subjected to 30 min. of hypoxia followed by 30 min. of reoxygenation, visfatin (100 ng/ml), administered at the time of
reoxygenation, reduced the cell death from 65.2  4.6% in control to 49.2  3.7% (n  200 cells/group, P  0.05), an effect that was
abrogated by wortmannin and U0126 (68.1  5.2% and 59.7  6.2%, respectively; n  200 cells/group, P  0.05). Finally, the treatment
of murine ventricular cardiomyocytes with visfatin (100 ng/ml) delayed the opening of the mPTP induced by oxidative stress from
81.2  4 sec. in control to 120  7 sec. (n  20 cells/group, P  0.05) in a PI3K- and MEK1/2-dependent manner. We report that the
adipocytokine, visfatin, is capable of reducing myocardial injury when administered at the time of myocardial reperfusion in both the in situ
murine heart and the isolated murine cardiomyocytes. The mechanism appears to involve the PI3K and MEK1/2 pathways and the mPTP.
Keywords: visfatin • ischaemia • reperfusion • cardioprotection
J. Cell. Mol. Med. Vol 12, No 4, 2008 pp. 1395-1403
*Correspondence to: Derek M. YELLON, D.Sc., 
The Hatter Cardiovascular Institute, University College London Hospital
and Medical School, 67 Chenies Mews, London WC1E 6HX, 
United Kingdom.
Tel.: 0044-207-380-9776; Fax: 0044-207-388-5095
E-mail: hatter-institute@ucl.ac.uk
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2008.00332.x1396
a non-specific mitochondrial channel whose opening in the first
few minutes of myocardial reperfusion is a critical determinant of
the cardiomyocyte death [16, 17]. In addition, several studies have
reported that the visfatin gene is induced in response to hypoxia,
an effect mediated by hypoxia-inducible factor [18, 19], raising the
possibility that visfatin is up-regulated in response to myocardial
ischaemia. In the current study, we have suggested that visfatin
elicits cardioprotection through the activation of PI3K-Akt and
MEK1/2-Erk1/2 and the subsequent inhibition of mPTP opening.
Methods
Animals and materials
Experiments were carried out in accordance with the United Kingdom
Home Office Guide on the Operation of Animal (Scientific Procedures) Act
of 1986. C57BL/6 male mice were obtained from Charles River UK Limited
(Margate, UK). Wortmannin (Tocris Bioscience, Bristol, UK), U0126 (Tocris
Bioscience) and cyclosporin A (CsA) (Calbiochem, San Diego, CA, USA)
were dissolved in dimethyl sulfoxide (DMSO) (0.02%). Visfatin (Alexis
Biochemical, Lausen, Switzerland) was dissolved in normal saline.
In vivo murine model of acute 
myocardial infarction
C57BL/6 male mice (8–12 weeks of age and weighing 25–30 g) were
anaesthetized by intraperitoneal injection with a combination of ketamine,
xylazine and atropine (0.01 ml/g; the final concentrations of ketamine,
xylazine and atropine were 10 mg/ml, 2 mg/ml and 0.06 mg/ml, respec-
tively) and their body temperature was maintained at 37°C. The external
jugular vein and carotid artery were isolated and cannulated for drug
administration and mean arterial blood pressure (MABP) measurement,
respectively. A tracheotomy was performed for artificial respiration at
120 strokes/min. and 200 l stroke volume using a rodent Minivent (type
845; Harvard Apparatus, Kent, United Kingdom) and supplemental oxygen
was supplied. A limb lead I electrocardiogram (ECG) was recorded. A left
anterior thoracotomy and a chest retractor were used to expose the heart.
Ligation of the left anterior descending (LAD) coronary artery was per-
formed ~2 mm below the tip of the left atrium using an 8/0 prolene
monofilament polypropylene suture. Successful LAD coronary artery
occlusion was confirmed by the presence of ST elevation and a decrease
in the arterial blood pressure. At the end of the reperfusion, the heart was
isolated and the aortic root was cannulated and used to inject 2,3,5-triph-
enyltetrazolium chloride (TTC, 5 ml of 1%) in order to demarcate the
infarcted tissue. The LAD coronary artery was then re-ligated and Evans
blue dye (2 ml of 0.5%) was perfused to delineate the area at risk (AAR).
The heart was frozen and sectioned perpendicular to the long axis (1- to
2-mm thick). The slices were then transferred to 10% neutral buffer for-
malin for 2 hrs at room temperature to stabilize the staining. The AAR and
infarct size were determined by computerized planimetry performed with
the National Institutes of Health (NIH) software Image (Bethesda, MD,
USA). The AAR was expressed as a percentage of the left ventricle and the
infarct size was expressed as a percentage of the AAR [20].
Experimental protocol for murine myocardial
infarction studies
C57BL/6 male mice were randomly assigned to one of the following six
treatment groups (Fig. 1). The hearts were subjected to 30 min. of
ischaemia, followed by 120 min. of reperfusion at the end of which the
infarct size was determined by tetrazolium staining.
1) Vehicle control (n 	 13): either 0.02% DMSO or normal saline (0.1
ml) was administered immediately prior to the onset of myocardial
reperfusion.
2) Visfatin (n 	 8): an intravenous bolus of Visfatin (5  10
6 mol,
0.1 ml) dissolved in normal saline was administered immediately
prior to the onset of myocardial reperfusion.
3) Visfatin 
 wortmannin (n 	 6): visfatin was administered in the
presence of wortmannin (15 g/kg) dissolved in DMSO (0.02%)
immediately prior to the onset of reperfusion.
4) Vistatin 
 U0126 (n 	 6): visfatin was administered in the presence
of U0126 (0.2 mg/kg) dissolved in DMSO (0.02%) immediately prior
to the onset of reperfusion.
5,6) Wortmannin or U0126 (n 	 4): wortmannin or U0126 was adminis-
tered alone immediately prior to the onset of reperfusion.
Experimental protocol for murine ventricular 
cardiomyocyte isolation
The mice were injected with heparin sodium (250 IU) and anaesthetized with
ketamine/xylazine/atropine. The hearts were rapidly excised, cannulated and
perfused with (in mmol/L) 113.0 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6 Na2HPO4,
1.2 MgSO4.7H2O, 12.0 NaHCO3, 10.0 KHCO3, 30.0 taurine, 10.0 HEPES, and
5.5 glucose, saturated with 95% O2–5% CO2 at 37°C. The hearts were per-
fused at 3 ml/min. with perfusion buffer for 4 min., then with perfusion buffer
containing 0.9 mg/ml collagenase type II (Worthington Biochemical
Corporation, Lakewood, NJ, USA) 0.125 mg/ml hyaluronidase and 12.5
mol/L CaCl2for 10 min. The ventricles were then cut into several pieces and
shaken at 37°C, with oxygenation for 10 min. The supernatant was collected
and 5% foetal calf serum was added. After centrifugation at 600 rpm for 3
min., the cell pellet was suspended in 10 ml of perfusion buffer containing
12.5 mol/L CaCl2 and the calcium concentration was gradually restored to
1 mmol/L over 20 min. The myocytes were re-centrifuged, then seeded onto
sterilized laminin-coated coverslips in minimum essential medium (MEM)
containing 10 units/ml penicillin, 10 g/ml streptomycin and 5% foetal calf
serum for incubation before use on the same day of isolation.
Experimental protocol for ventricular 
cardiomyocyte viability studies
All cells were subjected to 30 min. of hypoxia, then 30 min. of reoxygena-
tion to simulate ischaemia-reperfusion injury. Hypoxia was induced in a
custom-made airtight hypoxic chamber using a buffer simulating the 
conditions of ischaemia (in mmol/L: 1.0 KH2PO4, 10.0 NaHCO3, 
1.2 MgCl2.6H20, 25.0 Na(4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) (HEPES), 74.0 NaCl, 16.0 KCl, 1.2 CaCl2 and 20.0 Na lactate, pH 6.7),
bubbled with 95% nitrogen/5% CO2. Reoxygenation was achieved by
replacing the buffer with a solution containing (in mmol/L) 1.0 KH2PO4,
10.0 NaHCO3, 1.2 MgCl2.6H20, 25.0 NaHEPES, 98.0 NaCl, 3.0 KCl, 1.2 CaCl2,
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10.0 D-glucose, 2.0 Na pyruvate, pH 7.4, bubbled with 95% O2/5% CO2.
The cells were randomized to the following six treatment groups (n 
200 cells per group from three to six different animals).
1) Vehicle control: cells were reoxygenated in normal buffer or buffer
containing 0.02% DMSO.
2) Visfatin: cells were reoxygenated in buffer containing visfatin 
(100 ng/ml).
3) Visfatin 
 wortmannin: cells were reoxygenated in buffer containing
visfatin and wortmannin (100 nmol/L).
4) Vistatin  
 U0126: cells were reoxygenated in buffer containing 
visfatin and U0126 (10 mol/L).
5,6) Wortmannin or U0126: Cells were reoxygenated in buffer containing
either wortmannin or U0126.
At the end of the reoxygenation, 5 l of propidium iodide (PI, 1 g/ml)
was added to the cells for 5 min. followed by 1 ml of 10% neutral buffer
formalin. The percentage of dead cells (as indicated by red fluorescence,
PI-positive) in duplicate wells was calculated by fluoroscence microscopy
and was expressed as a percentage of the total number of cardiomyocytes
(PI-positive and PI-negative).
Assay of mPTP opening
The sensitivity of the mPTP to opening was assayed using a well-charac-
terized and reproducible cellular model [9, 15]. Live isolated myocytes
were incubated with the fluorescent dye tetra-methyl rhodamine methyl
ester (TMRM, 3 mol/L) for 15 min. in microscopy buffer (i.e. perfusion
buffer containing 1.2 mmol/L CaCl2), then washed and imaged using con-
focal microscopy. TMRM, a lipophilic cation, accumulates selectively into
the mitochondria according to the mitochondrial membrane potential.
Continual confocal laser scanning generates reactive oxygen species
(ROS) from the TMRM within the mitochondria that, after several minutes,
provoke mPTP opening, as indicated by the mitochondrial depolarization.
After loading with TMRM, and before confocal laser illumination, the car-
diomyocytes were randomly assigned to the following treatment groups 
(n  20 cells per group from three to five different mice):
1) Vehicle control: cardiomyocytes were bathed in buffer containing
either 0.02% DMSO or normal saline.
2) Visfatin: cardiomyocytes were treated with visfatin (100 ng/ml) for 
5 min.
3) Visfatin 
 wortmannin: cardiomyocytes were treated with visfatin
and wortmannin (100 nmol/L) for 5 min.
4) Vistatin 
 U0126: cardiomyocytes were treated with visfatin and
U0126 (10 mol/L) for 5 min.
5,6) Wortmannin or U0126: cardiomyocytes were treated with either
wortmannin or U0126 for 5 min.
7) CsA: cardiomyocytes were treated with CsA (0.4 mol/L) for 5 min.
Statistical analysis
All values are expressed as mean  standard error of mean (S.E.M.).
Infarct size to AAR, cell viability data and the time taken to induce mPTP
opening were analysed by one-way ANOVA followed by Dunnett’s multiple
comparison  post-hoc test. The differences were considered significant
when P  0.05.
Results
In general, except for the increase in MABP in the wortmannin-
treated hearts, the treatment with visfatin and/or the kinase
inhibitors had no significant effects on the haemodynamic param-
eters of MABP and heart rate (Table 1).
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Fig. 1 Experimental protocols for in
vivo murine infarction studies. All
hearts were subjected to 15 min. of
stabilization, 30 min. of regional
myocardial ischaemia, followed by
120 min. of myocardial reperfusion
at the end of which the infarct size
was determined by tetrazolium
staining. Visfatin was given immedi-
ately prior to the onset of myocardial
reperfusion in the presence or
absence of the PI3K and MEK1/2
inhibitors wortmannin and U0126,
respectively.1398
Visfatin reduces the myocardial infarct 
size in vivo when administered at 
the time of reperfusion through PI3K 
and MEK1/2
The AAR of myocardial infarction was comparable among the
treatment groups (42.1  2.0% in control versus 53.2  8.0%
visfatin, 53.6  8.0% visfatin 
 wortmannin, 47.2  5.0% vis-
fatin 
 U0126, 48.2  3.0% wortmannin, 49.2  9.0% U0126; P
 0.05). Visfatin, given at the time of myocardial reperfusion,
reduced the infarct size from 46.1  4.1% in control to 27.3 
4.0% (P  0.05; Fig. 2). Wortmannin and U0126 both abolished
the decrease in the infarct size observed in the visfatin-treated
hearts (46.1  4.1% in control versus 48.8  5.5% with visfatin

 wortmannin and 45.9  8.4% with visfatin and U0126; Fig. 2).
The administration of wortmannin or U0126 alone had no effect
on the infarct size (46.1  4.1% in control versus 51.2  5.1%
with wortmannin and 40.5  8.9% with U0126; P  0.05; Fig. 2).
The infarct size is plotted against the AAR in Fig. 3.
Visfatin reduces the cardiomyocyte death when
administered at the time of reoxygenation through 
PI3K and MEK1/2
In murine ventricular cardiomyocytes subjected to an episode of
sustained hypoxia, the presence of visfatin at the time of reoxy-
genation reduced the cell death from 65.2  4.6% in control to
49.2  3.7% with visfatin (P  0.05; Fig. 4). The cardioprotec-
tive effect of visfatin was abrogated in the presence of wortman-
nin and U0126 (65.2  4.6% in control versus 68.1  5.2% with
visfatin 
 wortmannin and 59.7  6.2% with visfatin 
 U0126;
P  0.05; Fig. 4). The kinase inhibitors alone did not influence
the cardiomyocyte viability (65.2  4.6% in control versus
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Table 1 Haemodynamic variables in mice treated with vehicle, visfatin  wortmannin or U0126 at reperfusion
Mean arterial blood pressure (MABP) and heart rate (HR) were taken at 0 and 15 min. into occlusion (I, 0 min. and I, 15 min.), and at 5, 30 and
120 min. into reperfusion (R, 5 min.; R, 30 min. and R, 120 min.). Wort, Wortmannin; U0, U0126; bpm, beats per minute. * indicates P  0.05
versus control.
Mean Arterial Blood Pressure (mmHg)
Time-Point
I, 0 min. I, 15 min. R, 5 min. R, 30 min. R, 120 min.
Control 119  4 98  4 98  4 85  3 49  4
Visfatin 114  6 90  6 84  8 80  4 51  5
Visfatin 
 wort 110  4 91  3 103  5 83  6 56  7
Visfatin 
 U0 120  4 102  4 99  5 85  2 64  3
Wort 123  7 102  7 122  9* 101  4* 47  8
U0 115  4 101  4 101  2 84  4 53  8
Heart Rate (bpm)
Time-Point
I, 0 min. I, 15 min. R, 5 min. R, 30 min. R, 120 min.
Control 354  9 349  10 344  7 354  9 388  15
Visfatin 369  9 334  10 337  11 340  6 370  9
Visfatin 
 wort 343  11 329  5 332  12 337  10 362  14
Visfatin 
 U0 351  12 341  15 347  16 366  14 395  8
Wort 385  19 361  12 384  17 373  14 386  14
U0 354  16 340  9 362  12 378  18 428  25J. Cell. Mol. Med. Vol 12, No 4, 2008
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58.3  5.5% with wortmannin and 54.5  1.4% with U0126; 
P  0.05; Fig. 4).
Visfatin delays the mPTP opening in a PI3K- and
MEK1/2-dependent manner
The treatment of cardiomyocytes with visfatin delayed the time
taken to induce mPTP opening from 81.2  4.0 sec. in control to
120.0  6.5 sec. with visfatin (P  0.01; Fig. 5). The effect of vis-
fatin on the mPTP opening was comparable in magnitude to treat-
ment with CsA (the archetypal mPTP inhibitor and a positive con-
trol) (81.2  4.0 sec. in control versus 121.5  8.4 sec. with CsA;
P  0.01; Fig. 5). The inhibitory effect of visfatin on the mPTP
opening was abrogated in the presence of the PI3K and MEK1/2
inhibitors, wortmannin and U0126, respectively (83.4  3.4 sec.
with visfatin 
 wortmannin and 80.9  8.1 sec. with visfatin 

U0126; P  0.05; Fig. 5). The kinase inhibitors alone did not
influence the cardiomyocyte mPTP opening (81.2  4.0 sec. in
control versus 75.7  6.5 sec. with wortmannin and 77.0  4.8
sec. with U0126; P  0.05; Fig. 5).
Discussion
The pivotal findings of the current study are as follows: (1) we
demonstrate for the first time that the administration of the novel
adipocytokine, visfatin, specifically at the time of myocardial
reperfusion, dramatically reduces the myocardial infarct size using
an in vivo murine infarction model; (2) the cardioprotective effect
induced by visfatin is demonstrated to be a direct cellular effect,
as demonstrated by the improved cardiomyocyte viability
observed using isolated cardiomyocytes treated with visfatin at
the time of reoxygenation; (3) visfatin treatment delays the
opening of the mPTP in isolated cardiomyocytes subjected to
oxidative stress and (4) importantly, the cardioprotective effect
is dependent on the activation of the pro-survival kinases, PI3K
and MEK1/2.
Visfatin has only recently been discovered as an adipocy-
tokine, and as such, its pathophysiological role, in common
with some of the other newer adipocytokines, remains to be
determined. Fukuhara et al. [11] first identified visfatin in 2005,
as an adipocytokine that appeared to lower the serum glucose
by mimicking the actions of insulin, thereby raising the exciting
possibility of a novel antidiabetic agent [11]. In the same study,
the authors demonstrated that visfatin phosphorylated the
insulin receptor, insulin receptor substrate-1 (IRS-1) and -2
(IRS-2), PI3K, Akt and MAPK [11]. However, whether visfatin
actually mediates its effects by binding to the insulin receptor
has been recently debated [21].
Given that visfatin has the ability to activate Akt and MAPK, and
the prior knowledge that these kinases belong to the reperfusion
injury salvage kinase (RISK) pathway [13, 14], a group of protein
kinases that on activation at the time of myocardial reperfusion
confer powerful cardioprotection, we were keen to determine
whether visfatin was able to confer protection against acute
myocardial ischaemia-reperfusion injury. In the present study,
although we demonstrated that specific pharmacological blockers
of the RISK pathway abolished the protection elicited by visfatin, a
limitation of our study is that we did not determine whether
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Fig. 2 Infarct size, expressed as a 
percentage of the area at risk (AAR), 
in hearts administered visfatin (5 
10
6 mol) at the time of myocardial
reperfusion, in the presence or absence
of the PI3K and MEK1/2 inhibitors wort-
mannin (Wort, 15 g/kg) and U0126
(0.2 mg/kg), respectively. Visfatin is
shown to reduce the myocardial infarct
size significantly, and this cardioprotec-
tive effect is abolished in the presence of
the kinase inhibitors. Numbers in paren-
theses indicate n numbers. *P  0.05.1400 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Cell viability following 30 min. of
hypoxia and 30 min. of reoxygenation in
murine ventricular cardiomyocytes treat-
ed with visfatin (100 ng/ml) in the pres-
ence or absence of the PI3K and MEK1/2
inhibitors wortmannin (Wort, 100 nmol/L)
and U0126 (10 mol/L), respectively.
Visfatin reduces the percentage car-
diomyocyte death elicited by hypoxia-
reoxygenation injury, and this cardiopro-
tective effect is abolished in the presence
of the kinase inhibitors. n  200 cells per
group. *P  0.05.
Fig. 3 Infarct size plotted against the area
at risk (AAR) for control hearts (A) and
visfatin-treated hearts (B).J. Cell. Mol. Med. Vol 12, No 4, 2008
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visfatin treatment resulted in the phosphorylation of kinases of Akt
and Erk1/2. Given that the cardioprotection mediated through the
RISK pathway has been linked to the inhibition of the mPTP [15],
a non-specific high-conductance channel of the inner mitochondr-
ial membrane that is believed to mediate lethal reperfusion injury
by opening in the first few minutes of myocardial reperfusion [16],
it was important in the current study to link the protective effect of
visfatin with the inhibition of mPTP opening. It must be appreciat-
ed that although the model we used to detect mPTP opening in the
current study is a well-established and reproducible model [9, 15],
it was limited by the fact that it only reproduced the oxidative
stress component of ischaemia-reperfusion injury to provoke
mPTP opening.
As described above, the pathophysiological role of visfatin is
currently unclear. The clinical studies in which plasma levels of
visfatin were measured in different patient groups showed no
clear correlations. Indeed, measurements of plasma visfatin lev-
els in human beings have yielded conflicting results, with raised
levels being reported in obese children [22], diabetic patients
[23, 24], patients after weight loss mediated by gastroplastic
surgery [25] and patients being treated with thiazolidinedione
and rosiglitazone [26], whilst other studies have reported
reduced levels with gestational diabetes [27], exercise in
patients with type 1 diabetes [28], massive weight loss [29] and
obesity [30].
Interestingly, visfatin was formerly identified as a pre-B cell
colony-enhancing factor (PBEF) [31], a growth factor for early B
cells, which has been linked to a diverse variety of cellular processes,
with studies demonstrating PBEF to (a) act as a biomarker of acute
lung injury [32, 33], (b) be up-regulated in infected foetal mem-
branes [34], (c) inhibit neutrophil apoptosis in experimental inflam-
mation and clinical sepsis [12] and (d) participate in the maturation
of vascular smooth muscle cells through a nicotinamide adenine
dinucleotide (NAD

)-dependent mechanism [35].
Intriguingly, PBEF/visfatin has also been identified as the
enzyme nicotinamide phosphoribosyl transferase (Nampt), the
rate-limiting enzyme in NAD biosynthesis that mediates the con-
version of nicotinamide to nicotinamide mononucleotide [36].
Given the pivotal role of Nampt in NAD biosynthesis, pharmaco-
logical inhibitors of Nampt such as FK866 are currently being
investigated as potential novel anticancer agents [37, 38]. Clearly,
further studies are required to elucidate the pathophysiological
role of visfatin in relation to these previous identities of PBEF and
Nampt. For example, the possibility that the cardioprotective effect
elicited by visfatin could be due to the potentiation of Nampt,
which would be expected to up-regulate NAD biosynthesis, there-
by enhancing energy metabolism and redox biochemistry, factors
that underpin the tolerance of myocardial tissue to ischaemic
injury, requires investigation.
Whether endogenous visfatin contributes to cardioprotection
in the clinical setting is unclear; but in this regard, it is interesting
that the experimental studies have reported that the visfatin gene
is induced in response to hypoxia, an effect mediated by hypoxia-
inducible factor [18, 19], raising the possibility that visfatin may
be up-regulated in response to myocardial ischaemia. Thus, fur-
ther studies are required to ascertain the plasma levels of visfatin
in patients presenting with an acute myocardial infarction. The
recent investigations have linked visfatin with MAPK-mediated
angiogenesis [39] as well as a potential pro-inflammatory
mediator in unstable atherosclerotic plaques, suggesting that
endogenous visfatin may have a detrimental effect in coronary
artery disease [40]. In the current study, we found that the acute
administration of exogenous visfatin can protect against acute
myocardial ischaemia-reperfusion injury in a non-atherosclerotic
animal model of myocardial infarction and in isolated cardiomy-
ocytes. Further studies will be required to determine whether
exogenous visfatin elicits the same cardioprotective benefits in the
atherosclerotic models of myocardial infarction.
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 The time taken to induce mito-
chondrial permeability transition pore
(mPTP) opening in murine ventricular
cardiomyocytes treated with visfatin 
(100 ng/ml) in the presence or absence of
the PI3K and MEK1/2 inhibitors wortman-
nin (Wort, 100 nmol/L) and U0126 
(10 mol/L), respectively. Visfatin delays
the time taken to induce mPTP opening,
an effect that is abolished in the presence
of the kinase inhibitors. n  20 cells per
group. *P  0.01.1402
In summary, this study has demonstrated, for the first time,
that the novel adipocytokine, visfatin, has the ability to reduce
the myocardial infarct size when administered at the time of
myocardial reperfusion. This powerful cardioprotective effect
appears to be a direct cellular effect that is mediated through
the activation of PI3K and MEK1/2 and the inhibition of mPTP
opening.
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